Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.

Heuck CJ, Szymonifka J, Hansen E, Shaughnessy JD Jr, Usmani SZ, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Bailey C, Epstein J, Hoering A, Crowley J, Barlogie B.

Clin Cancer Res. 2012 Oct 1;18(19):5499-506. doi: 10.1158/1078-0432.CCR-12-0019. Epub 2012 Aug 1. Erratum in: Clin Cancer Res. 2013 Feb 1;19(3):752.

2.

Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival.

Nair B, Shaughnessy JD Jr, Zhou Y, Astrid-Cartron M, Qu P, van Rhee F, Anaissie E, Alsayed Y, Waheed S, Hollmig K, Szymonifka J, Petty N, Hoering A, Barlogie B.

Blood. 2009 Jun 25;113(26):6572-5. doi: 10.1182/blood-2009-02-207803. Epub 2009 Apr 23.

3.

Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma.

Maiolino A, Hungria VT, Garnica M, Oliveira-Duarte G, Oliveira LC, Mercante DR, Miranda EC, Quero AA, Peres AL, Barros JC, Tanaka P, Magalhães RP, Rego EM, Lorand-Metze I, Lima CS, Renault IZ, Braggio E, Chiattone C, Nucci M, de Souza CA; Brazilian Multiple Myeloma Study Group (BMMSG/GEMOH).

Am J Hematol. 2012 Oct;87(10):948-52. doi: 10.1002/ajh.23274. Epub 2012 Jun 23.

4.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M.

J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

PMID:
24449241
5.

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B.

Blood. 2010 May 27;115(21):4168-73. doi: 10.1182/blood-2009-11-255620. Epub 2010 Feb 2.

6.

Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.

Mileshkin L, Honemann D, Gambell P, Trivett M, Hayakawa Y, Smyth M, Beshay V, Ritchie D, Simmons P, Milner AD, Zeldis JB, Prince HM.

Haematologica. 2007 Aug;92(8):1075-82. Epub 2007 Jul 20.

7.

Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial.

Ho PJ, Brown RD, Spencer A, Jeffels M, Daniher D, Gibson J, Joshua DE.

Leuk Lymphoma. 2012 Sep;53(9):1728-34. doi: 10.3109/10428194.2012.664842. Epub 2012 Mar 13.

PMID:
22329352
8.

Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.

Krejci M, Scudla V, Tothova E, Schutzova M, Koza V, Adam Z, Krivanova A, Pour L, Buchler T, Sandecka V, Kralova D, Zahradova L, Vorlicek J, Mayer J, Hajek R.

Clin Lymphoma Myeloma. 2009 Dec;9(6):436-42. doi: 10.3816/CLM.2009.n.086.

PMID:
19951883
9.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

PMID:
21670455
10.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B.

Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31.

11.

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study.

Morabito F, Bringhen S, Larocca A, Wijermans P, Victoria Mateos M, Gimsing P, Mazzone C, Gottardi D, Omedè P, Zweegman S, José Lahuerta J, Zambello R, Musto P, Magarotto V, Schaafsma M, Oriol A, Juliusson G, Cerrato C, Catalano L, Gentile M, Isabel Turel A, Marina Liberati A, Cavalli M, Rossi D, Passera R, Rosso S, Beksac M, Cavo M, Waage A, San Miguel J, Boccadoro M, Sonneveld P, Palumbo A, Offidani M.

Am J Hematol. 2014 Apr;89(4):355-62. doi: 10.1002/ajh.23641. Epub 2014 Feb 5.

12.

Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.

Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF, Coyle L, Gill DS, Horvath N, Reynolds J, Kennedy N.

J Clin Oncol. 2009 Apr 10;27(11):1788-93. doi: 10.1200/JCO.2008.18.8573. Epub 2009 Mar 9.

PMID:
19273705
13.

The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.

Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C.

J Clin Oncol. 2011 Nov 1;29(31):4079-87. doi: 10.1200/JCO.2011.35.4423. Epub 2011 Sep 26.

PMID:
21947824
14.

Focus on high-risk DTC patients: high postoperative serum thyroglobulin level is a strong predictor of disease persistence and is associated to progression-free survival and overall survival.

Piccardo A, Arecco F, Puntoni M, Foppiani L, Cabria M, Corvisieri S, Arlandini A, Altrinetti V, Bandelloni R, Orlandi F.

Clin Nucl Med. 2013 Jan;38(1):18-24. doi: 10.1097/RLU.0b013e318266d4d8.

PMID:
23242039
15.

Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.

Offidani M, Corvatta L, Polloni C, Piersantelli MN, Gentili S, Galieni P, Visani G, Alesiani F, Catarini M, Brunori M, Samori A, Burattini M, Centurioni R, Ferranti M, Giuliodori L, Candela M, Mele A, Marconi M, Leoni P.

Br J Haematol. 2009 Mar;144(5):653-9. doi: 10.1111/j.1365-2141.2008.07495.x. Epub 2008 Nov 13.

PMID:
19036082
16.

Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.

Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, Murakami H, Hayashi K, Mina R, Palumbo A, Shimizu K; Japanese Society of Myeloma; European Myeloma Network.

Acta Haematol. 2014;132(2):211-9.

PMID:
24662986
17.

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.

Schütt P, Ebeling P, Buttkereit U, Brandhorst D, Opalka B, Poser M, Müller S, Flasshove M, Moritz T, Seeber S, Nowrousian MR.

Ann Hematol. 2005 Sep;84(9):594-600. Epub 2005 Mar 3.

PMID:
15744524
18.

Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.

Chen QY, Wen YF, Guo L, Liu H, Huang PY, Mo HY, Li NW, Xiang YQ, Luo DH, Qiu F, Sun R, Deng MQ, Chen MY, Hua YJ, Guo X, Cao KJ, Hong MH, Qian CN, Mai HQ.

J Natl Cancer Inst. 2011 Dec 7;103(23):1761-70. doi: 10.1093/jnci/djr432. Epub 2011 Nov 4.

PMID:
22056739
19.

Predicting durable remissions following thalidomide therapy for relapsed myeloma.

Quach H, Mileshkin L, Seymour JF, Milner A, Ritchie D, Harrison S, Westerman D, Prince HM.

Leuk Lymphoma. 2009 Feb;50(2):223-9. doi: 10.1080/10428190802663213.

PMID:
19194832
20.

[Maintenance therapies of thalidomine and interferon-α in multiple myeloma].

Li J, Cai JH, Huang BH, Liu JR, Zheng D.

Zhonghua Yi Xue Za Zhi. 2011 Dec 27;91(48):3417-20. Chinese.

PMID:
22333255

Supplemental Content

Support Center